{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T20:07:53Z","timestamp":1789157273681,"version":"build-2803163510"},"reference-count":43,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Hunan Provincial Natural Science Foundation","doi-asserted-by":"publisher","award":["2024JJ4094"],"award-info":[{"award-number":["2024JJ4094"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82200536"],"award-info":[{"award-number":["82200536"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82572076"],"award-info":[{"award-number":["82572076"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82203931"],"award-info":[{"award-number":["82203931"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["ard.eular.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of the Rheumatic Diseases"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ard.2026.06.030","type":"journal-article","created":{"date-parts":[[2026,7,23]],"date-time":"2026-07-23T11:35:42Z","timestamp":1784806542000},"page":"1761-1773","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["CNS immune remodelling in SLE associated with anti-CD19 CAR-T therapy"],"prefix":"10.1016","volume":"85","author":[{"given":"Jinjian","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoru","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weina","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zuge","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shouli","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wanhan","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cuiwei","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhen","family":"Xia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hui","family":"Luo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongjun","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5267-2456","authenticated-orcid":false,"given":"Yuzi","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10441","key":"10.1016\/j.ard.2026.06.030_bib0001","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1016\/S0140-6736(24)00398-2","article-title":"Systemic lupus erythematosus","volume":"403","author":"Hoi","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.ard.2026.06.030_bib0002","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1016\/j.it.2017.02.001","article-title":"Expanding the B cell-centric view of systemic lupus erythematosus","volume":"38","author":"Morawski","year":"2017","journal-title":"Trends Immunol."},{"issue":"2","key":"10.1016\/j.ard.2026.06.030_bib0003","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1038\/s41584-024-01210-9","article-title":"Opportunities and limitations of B cell depletion approaches in SLE","volume":"21","author":"Stockfelt","year":"2025","journal-title":"Nat Rev Rheumatol."},{"issue":"14","key":"10.1016\/j.ard.2026.06.030_bib0004","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1182\/blood.2023022922","article-title":"The present and future of CAR T-cell therapy for adult B-cell ALL","volume":"145","author":"Rampotas","year":"2025","journal-title":"Blood."},{"issue":"10","key":"10.1016\/j.ard.2026.06.030_bib0005","doi-asserted-by":"crossref","DOI":"10.1016\/j.medj.2025.100749","article-title":"Allogeneic CD19-targeted CAR-T therapy in refractory systemic lupus erythematosus achieved durable remission","volume":"6","author":"Wang","year":"2025","journal-title":"Med."},{"issue":"8","key":"10.1016\/j.ard.2026.06.030_bib0006","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1056\/NEJMoa2308917","article-title":"CD19 CAR T-cell therapy in autoimmune disease - a case series with follow-up","volume":"390","author":"M\u00fcller","year":"2024","journal-title":"N Engl J Med."},{"issue":"10","key":"10.1016\/j.ard.2026.06.030_bib0007","doi-asserted-by":"crossref","first-page":"1304","DOI":"10.1136\/ard-2024-225785","article-title":"BCMA-CD19 compound CAR T cells for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Wang","year":"2024","journal-title":"Ann Rheum Dis."},{"issue":"10437","key":"10.1016\/j.ard.2026.06.030_bib0008","doi-asserted-by":"crossref","first-page":"1627","DOI":"10.1016\/S0140-6736(24)00424-0","article-title":"CAR T-cell therapy rescues adolescent with rapidly progressive lupus nephritis from haemodialysis","volume":"403","author":"Krickau","year":"2024","journal-title":"Lancet."},{"key":"10.1016\/j.ard.2026.06.030_bib0009","doi-asserted-by":"crossref","DOI":"10.1016\/j.eclinm.2025.103229","article-title":"Safety and clinical efficacy of Relmacabtagene autoleucel (relma-cel) for systemic lupus erythematosus: a phase 1 open-label clinical trial","volume":"83","author":"Shu","year":"2025","journal-title":"EClinicalMedicine."},{"issue":"1","key":"10.1016\/j.ard.2026.06.030_bib0010","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1136\/ard-2024-226142","article-title":"CD19-CAR T-cell therapy induces deep tissue depletion of B cells","volume":"84","author":"Tur","year":"2025","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"10.1016\/j.ard.2026.06.030_bib0011","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1186\/s12943-023-01783-1","article-title":"Deciphering and advancing CAR T-cell therapy with single-cell sequencing technologies","volume":"22","author":"Huang","year":"2023","journal-title":"Mol Cancer."},{"issue":"11","key":"10.1016\/j.ard.2026.06.030_bib0012","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1038\/s41584-024-01163-z","article-title":"Recent advances in the diagnosis and management of neuropsychiatric lupus","volume":"20","author":"Legge","year":"2024","journal-title":"Nat Rev Rheumatol"},{"issue":"4","key":"10.1016\/j.ard.2026.06.030_bib0013","doi-asserted-by":"crossref","DOI":"10.1016\/j.autrev.2021.102780","article-title":"Neuropsychiatric involvement in systemic lupus erythematosus: a review","volume":"20","author":"Carri\u00f3n-Barber\u00e0","year":"2021","journal-title":"Autoimmun Rev."},{"issue":"8","key":"10.1016\/j.ard.2026.06.030_bib0014","doi-asserted-by":"crossref","first-page":"1342","DOI":"10.1016\/j.ard.2025.04.006","article-title":"Enhanced B cell and complement cascade gene signatures in patients with neuropsychiatric systemic lupus erythematosus","volume":"84","author":"Nikolopoulos","year":"2025","journal-title":"Ann Rheum Dis."},{"issue":"1","key":"10.1016\/j.ard.2026.06.030_bib0015","doi-asserted-by":"crossref","first-page":"7271","DOI":"10.1038\/s41467-025-61822-x","article-title":"Integrative multi-omics reveals a regulatory and exhausted T-cell landscape in CLL and identifies galectin-9 as an immunotherapy target","volume":"16","author":"Lla\u00f3-Cid","year":"2025","journal-title":"Nat Commun."},{"issue":"1","key":"10.1016\/j.ard.2026.06.030_bib0016","doi-asserted-by":"crossref","DOI":"10.1172\/JCI177793","article-title":"A single-cell compendium of human cerebrospinal fluid identifies disease-associated immune cell populations","volume":"135","author":"Cantoni","year":"2025","journal-title":"J Clin Invest."},{"issue":"673","key":"10.1016\/j.ard.2026.06.030_bib0017","doi-asserted-by":"crossref","first-page":"eadc9778","DOI":"10.1126\/scitranslmed.adc9778","article-title":"A single-cell analysis framework allows for characterization of CSF leukocytes and their tissue of origin in multiple sclerosis","volume":"14","author":"Ostkamp","year":"2022","journal-title":"Sci Transl Med."},{"key":"10.1016\/j.ard.2026.06.030_bib0018","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.semcdb.2017.12.009","article-title":"Dendritic cell subsets","volume":"84","author":"Macri","year":"2018","journal-title":"Semin Cell Dev Biol"},{"issue":"4","key":"10.1016\/j.ard.2026.06.030_bib0019","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transplant."},{"key":"10.1016\/j.ard.2026.06.030_bib0020","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2020.577027","article-title":"Cytokines in CAR T cell-associated neurotoxicity","volume":"11","author":"Gust","year":"2020","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.ard.2026.06.030_bib0021","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1002\/ana.25502","article-title":"Glial injury in neurotoxicity after pediatric CD19-directed chimeric antigen receptor T cell therapy","volume":"86","author":"Gust","year":"2019","journal-title":"Ann Neurol."},{"issue":"12","key":"10.1016\/j.ard.2026.06.030_bib0022","doi-asserted-by":"crossref","first-page":"1404","DOI":"10.1158\/2159-8290.CD-17-0698","article-title":"Endothelial activation and blood-brain barrier disruption in neurotoxicity after adoptive immunotherapy with CD19 CAR-T cells","volume":"7","author":"Gust","year":"2017","journal-title":"Cancer Discov."},{"issue":"8","key":"10.1016\/j.ard.2026.06.030_bib0023","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1158\/2159-8290.CD-17-1319","article-title":"Clinical and biological correlates of neurotoxicity associated with CAR T-cell therapy in patients with B-cell acute lymphoblastic leukemia","volume":"8","author":"Santomasso","year":"2018","journal-title":"Cancer Discov."},{"issue":"1","key":"10.1016\/j.ard.2026.06.030_bib0024","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1186\/s13073-025-01498-6","article-title":"The CXCL16\/CXCR6 axis is linked to immune effector cell-associated neurotoxicity in chimeric antigen receptor (CAR) T cell therapy","volume":"17","author":"Lu","year":"2025","journal-title":"Genome Med."},{"issue":"6","key":"10.1016\/j.ard.2026.06.030_bib0025","doi-asserted-by":"crossref","first-page":"1001","DOI":"10.1182\/bloodadvances.2022008119","article-title":"GFAP and NfL increase during neurotoxicity from high baseline levels in pediatric CD19-CAR T-cell patients","volume":"7","author":"Gust","year":"2023","journal-title":"Blood Adv."},{"issue":"10","key":"10.1016\/j.ard.2026.06.030_bib0026","doi-asserted-by":"crossref","first-page":"1351","DOI":"10.1038\/s41409-025-02679-y","article-title":"ICANS risk model in CD19 CAR-T therapy: insights from serum and CSF cytokine profiling","volume":"60","author":"Gomez-Llobell","year":"2025","journal-title":"Bone Marrow Transplant."},{"issue":"7","key":"10.1016\/j.ard.2026.06.030_bib0027","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1038\/s41571-024-00903-0","article-title":"Current understanding and management of CAR T cell-associated toxicities","volume":"21","author":"Brudno","year":"2024","journal-title":"Nat Rev Clin Oncol"},{"issue":"51","key":"10.1016\/j.ard.2026.06.030_bib0028","doi-asserted-by":"crossref","first-page":"37191","DOI":"10.1074\/jbc.M706150200","article-title":"Crystal structure of the interleukin-15.interleukin-15 receptor alpha complex: insights into trans and cis presentation","volume":"282","author":"Olsen","year":"2007","journal-title":"J Biol Chem."},{"key":"10.1016\/j.ard.2026.06.030_bib0029","doi-asserted-by":"crossref","DOI":"10.1016\/j.nicl.2023.103390","article-title":"Abnormal cerebral hemodynamics and blood-brain barrier permeability detected with perfusion MRI in systemic lupus erythematosus patients","volume":"38","author":"Salomonsson","year":"2023","journal-title":"Neuroimage Clin."},{"issue":"9","key":"10.1016\/j.ard.2026.06.030_bib0030","doi-asserted-by":"crossref","first-page":"2188","DOI":"10.1038\/s41423-021-00749-x","article-title":"Phase I study of CAR-T cells with PD-1 and TCR disruption in mesothelin-positive solid tumors","volume":"18","author":"Wang","year":"2021","journal-title":"Cell Mol Immunol."},{"issue":"9","key":"10.1016\/j.ard.2026.06.030_bib0031","doi-asserted-by":"crossref","first-page":"2098","DOI":"10.1158\/2159-8290.CD-21-1508","article-title":"Common trajectories of highly effective CD19-specific CAR T cells identified by endogenous T-cell receptor lineages","volume":"12","author":"Wilson","year":"2022","journal-title":"Cancer Discov."},{"issue":"2","key":"10.1016\/j.ard.2026.06.030_bib0032","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/j.ymthe.2020.11.028","article-title":"Single-cell transcriptomic analysis reveals BCMA CAR-T cell dynamics in a patient with refractory primary plasma cell leukemia","volume":"29","author":"Li","year":"2021","journal-title":"Mol Ther."},{"issue":"6589","key":"10.1016\/j.ard.2026.06.030_bib0033","doi-asserted-by":"crossref","first-page":"eabf1970","DOI":"10.1126\/science.abf1970","article-title":"Single-cell RNA-seq reveals cell type-specific molecular and genetic associations to lupus","volume":"376","author":"Perez","year":"2022","journal-title":"Science."},{"issue":"6","key":"10.1016\/j.ard.2026.06.030_bib0034","doi-asserted-by":"crossref","first-page":"586","DOI":"10.1097\/BOR.0000000000000815","article-title":"The role of CD8+ T-cell systemic lupus erythematosus pathogenesis: an update","volume":"33","author":"Chen","year":"2021","journal-title":"Curr Opin Rheumatol."},{"issue":"1","key":"10.1016\/j.ard.2026.06.030_bib0035","doi-asserted-by":"crossref","first-page":"7767","DOI":"10.1038\/s41467-023-43656-7","article-title":"CAR+ and CAR\u2013 T cells share a differentiation trajectory into an NK-like subset after CD19 CAR T cell infusion in patients with B cell malignancies","volume":"14","author":"Louie","year":"2023","journal-title":"Nat Commun."},{"issue":"95","key":"10.1016\/j.ard.2026.06.030_bib0036","doi-asserted-by":"crossref","first-page":"eadj9730","DOI":"10.1126\/sciimmunol.adj9730","article-title":"Single-cell analysis of anti-BCMA CAR T cell therapy in patients with central nervous system autoimmunity","volume":"9","author":"Qin","year":"2024","journal-title":"Sci Immunol."},{"issue":"12","key":"10.1016\/j.ard.2026.06.030_bib0037","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.179433","article-title":"Selective CAR T cell-mediated B cell depletion suppresses IFN signature in SLE","volume":"9","author":"Wilhelm","year":"2024","journal-title":"JCI Insight."},{"issue":"2","key":"10.1016\/j.ard.2026.06.030_bib0038","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41577-021-00547-6","article-title":"Cytokine release syndrome and associated neurotoxicity in cancer immunotherapy","volume":"22","author":"Morris","year":"2022","journal-title":"Nat Rev Immunol."},{"issue":"7","key":"10.1016\/j.ard.2026.06.030_bib0039","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1016\/j.jtct.2023.04.001","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transplant Cell Ther."},{"issue":"1","key":"10.1016\/j.ard.2026.06.030_bib0040","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J Immunother Cancer."},{"issue":"6","key":"10.1016\/j.ard.2026.06.030_bib0041","doi-asserted-by":"crossref","first-page":"e255","DOI":"10.1016\/S1470-2045(23)00159-6","article-title":"Prevention and management of adverse events during treatment with bispecific antibodies and CAR T cells in multiple myeloma: a consensus report of the European Myeloma Network","volume":"24","author":"Ludwig","year":"2023","journal-title":"Lancet Oncol."},{"issue":"4","key":"10.1016\/j.ard.2026.06.030_bib0042","doi-asserted-by":"crossref","first-page":"e203","DOI":"10.1016\/S1470-2045(24)00715-0","article-title":"Non-ICANS neurological complications after CAR T-cell therapies: recommendations from the EBMT Practice Harmonisation and Guidelines Committee","volume":"26","author":"Graham","year":"2025","journal-title":"Lancet Oncol."},{"issue":"3","key":"10.1016\/j.ard.2026.06.030_bib0043","doi-asserted-by":"crossref","first-page":"176","DOI":"10.1038\/s41434-018-0019-6","article-title":"Fludarabine and neurotoxicity in engineered T-cell therapy","volume":"25","author":"Lowe","year":"2018","journal-title":"Gene Ther."}],"container-title":["Annals of the Rheumatic Diseases"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726004164?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0003496726004164?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,11]],"date-time":"2026-09-11T19:19:37Z","timestamp":1789154377000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0003496726004164"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":43,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S0003496726004164"],"URL":"https:\/\/doi.org\/10.1016\/j.ard.2026.06.030","relation":{},"ISSN":["0003-4967"],"issn-type":[{"value":"0003-4967","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"CNS immune remodelling in SLE associated with anti-CD19 CAR-T therapy","name":"articletitle","label":"Article Title"},{"value":"Annals of the Rheumatic Diseases","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ard.2026.06.030","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Alliance of Associations for Rheumatology (EULAR). Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}